Amalgamated Bank Sells 968 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Amalgamated Bank reduced its position in shares of Inari Medical, Inc. (NASDAQ:NARIFree Report) by 2.9% in the third quarter, HoldingsChannel reports. The firm owned 32,381 shares of the company’s stock after selling 968 shares during the quarter. Amalgamated Bank’s holdings in Inari Medical were worth $2,118,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in NARI. BlackRock Inc. boosted its holdings in shares of Inari Medical by 13.0% in the second quarter. BlackRock Inc. now owns 6,385,806 shares of the company’s stock worth $371,271,000 after buying an additional 733,738 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Inari Medical by 46.8% during the 1st quarter. Wellington Management Group LLP now owns 4,626,607 shares of the company’s stock worth $419,355,000 after acquiring an additional 1,475,313 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Inari Medical by 6.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,243,238 shares of the company’s stock valued at $308,229,000 after acquiring an additional 242,983 shares during the period. Capital International Investors increased its stake in shares of Inari Medical by 0.8% in the 1st quarter. Capital International Investors now owns 2,838,045 shares of the company’s stock worth $257,240,000 after purchasing an additional 22,159 shares in the last quarter. Finally, Alliancebernstein L.P. raised its holdings in Inari Medical by 12.0% in the 2nd quarter. Alliancebernstein L.P. now owns 2,305,171 shares of the company’s stock worth $134,023,000 after purchasing an additional 247,389 shares during the period. Hedge funds and other institutional investors own 87.75% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on NARI shares. Piper Sandler cut their price target on Inari Medical from $90.00 to $85.00 and set an “overweight” rating for the company in a report on Thursday, November 2nd. Needham & Company LLC started coverage on Inari Medical in a research note on Tuesday, January 23rd. They set a “buy” rating and a $72.00 price objective for the company. Finally, Truist Financial raised their target price on shares of Inari Medical from $65.00 to $70.00 and gave the stock a “hold” rating in a research note on Friday, December 22nd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $81.29.

View Our Latest Stock Report on Inari Medical

Inari Medical Price Performance

Shares of NARI opened at $57.99 on Tuesday. The firm has a market cap of $3.34 billion, a P/E ratio of -966.50 and a beta of 0.93. Inari Medical, Inc. has a 1 year low of $47.81 and a 1 year high of $71.85. The company has a 50 day simple moving average of $60.98 and a two-hundred day simple moving average of $61.60.

Insider Activity at Inari Medical

In other Inari Medical news, Director William Hoffman sold 25,000 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $65.08, for a total transaction of $1,627,000.00. Following the completion of the transaction, the director now owns 1,045,493 shares of the company’s stock, valued at approximately $68,040,684.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director William Hoffman sold 25,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $65.08, for a total value of $1,627,000.00. Following the sale, the director now directly owns 1,045,493 shares in the company, valued at $68,040,684.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Andrew Hykes sold 37,448 shares of the stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $59.82, for a total value of $2,240,139.36. Following the transaction, the chief executive officer now directly owns 434,817 shares of the company’s stock, valued at $26,010,752.94. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 119,399 shares of company stock valued at $7,328,493. Corporate insiders own 13.70% of the company’s stock.

Inari Medical Profile

(Free Report)

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy systems for the specific disease states in the United States. The company provides ClotTriever, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases.

Featured Articles

Want to see what other hedge funds are holding NARI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inari Medical, Inc. (NASDAQ:NARIFree Report).

Institutional Ownership by Quarter for Inari Medical (NASDAQ:NARI)

Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.